E-QURE CORP. (OTCMKTS:EQUR) Files An 8-K Other Events
Item 8.01 Other Events

On November 11, 2016, E-Qure Corp., a Delaware corporation (the "Registrant"), reported on Form 8-K that on October 14, 2016, the Registrant received notification from FDA that it had been granted conditional approval to the IDE application, authorizing the Registrant to commence a clinical investigation of our BST Device with 10 patients at a single site.

On February17, 2017, the Registrant received FDA’s IDE approval letter which authorized the Registrant to begin a new 10-patient feasibility study to be conducted at up to 5 sites rather than the October 14, 2016 FDA approval for only one site. The FDA approval for expanding the study should expedite the Registrant’s ability to enlist patients for the study. The Registrant plans to submit a safety report with the FDA following which we intend to proceed with a trial, which contemplates testing the BST Device with 90 patients.

About E-QURE CORP. (OTCMKTS:EQUR)

E-Qure Corp. owns intellectual property (IP) of technology of wound healing device. The IP assets, including the wound healing device, are designed for wound treatment incorporating Bioelectrical Signal Therapy (BST Device). The BST Device implements electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The BST Device, using electrodes affixed around the opposing sides of the wound, emits an electrical field around the wound and therefore mimics the electrochemical physiology principle and induces local cell regeneration. The BST Device is used to treat severe stage II, as well as stage III and IV wounds, including pressure ulcers, diabetic ulcers and venous ulcers. The BST Device is a device for adjunctive therapy in wound healing. The BST Device is able to automatically adjust the electric pulse amplitude based on a patient’s impedance reading.

E-QURE CORP. (OTCMKTS:EQUR) Recent Trading Information

E-QURE CORP. (OTCMKTS:EQUR) closed its last trading session up +0.310 at 0.510 with 5,000 shares trading hands.